[HTML][HTML] Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy

…, M Mukamel, I Voth, PJ Hashkes, L Harel… - … England Journal of …, 2014 - Mass Medical Soc
Background Polyarteritis nodosa is a systemic necrotizing vasculitis with a pathogenesis
that is poorly understood. We identified six families with multiple cases of systemic and …

Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study

J Amir, L Harel, Z Smetana, I Varsano - Bmj, 1997 - bmj.com
Objectives: To examine the efficacy of aciclovir suspension for treating herpetic gingivostomatitis
in young children. Design: Randomised double blind placebo controlled study. Setting: …

Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

…, G Ganser, V Gerloni, JP Haas, L Harel… - The Lancet Child & …, 2019 - thelancet.com
Background To our knowledge, the characteristics and burden of childhood arthritis have
never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study…

Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies.

L Harel, C Sandborg, T Lee… - The Journal of …, 2006 - jrheum.org
OBJECTIVE: To determine the prevalence of neuropsychiatric (NP) manifestations in
children with systemic lupus erythematosus (SLE) using the 1999 American College of …

Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab

…, J Barash, Y Berkun, R Brik, L Harel… - Arthritis & …, 2016 - Wiley Online Library
Objective In pivotal trials, canakinumab has been shown to be effective in the treatment of
systemic juvenile idiopathic arthritis (JIA), but reported adverse events have included …

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

…, G Amarilyo, Y Butbul, Y Uziel, I Tirosh, L Harel… - The Lancet, 2023 - thelancet.com
Background Juvenile idiopathic arthritis can be refractory to some or all treatment regimens,
therefore new medications are needed to treat this population. This trial assessed the …

Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial

…, E Somekh, R Brik, J Barash, M Mukamel, L Harel… - The Journal of …, 2003 - Elsevier
We performed a prospective, randomized, open-label equivalence study comparing the use
of naproxen to aspirin in 33 patients with rheumatic fever. The mean time until resolution of …

Pro-and anti-inflammatory cytokines in children with febrile convulsions

R Straussberg, J Amir, L Harel, I Punsky, H Bessler - Pediatric neurology, 2001 - Elsevier
The production of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and IL-10 by peripheral
blood mononuclear cells was examined in 13 children with and 11 children without any …

[HTML][HTML] Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

…, R Schneider, V Gerloni, L Harel… - Arthritis research & …, 2017 - Springer
Background Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody
neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to …

Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study

L Harel, D Prais, E Bar-On, G Livni… - Journal of Pediatric …, 2011 - journals.lww.com
Liora Harel and Dario Prais contributed equally to this work as first authors. Reprints: Liora
Harel, MD, Department of Pediatrics C, … Other articles in this journal by Liora Harel, MD …